Compare Stocks → Everybody laughed when he recommended Netflix (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSE:BLUANASDAQ:NVCNNASDAQ:NVNONASDAQ:STIM Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLUABlueRiver Acquisition$11.02-0.3%$10.93$10.24▼$11.45$96.21MN/A31,504 shs500 shsNVCNNeovasc$30.03$29.69$4.59▼$30.07$82.28M1.756,993 shs1 shsNVNOenVVeno Medical$5.00+0.2%$5.27$2.51▼$6.97$66.65M1.1103,048 shs52,612 shsSTIMNeuronetics$2.53-3.1%$3.82$1.03▼$5.07$75.90M2.5181,818 shs69,823 shsThe Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLUABlueRiver Acquisition0.00%0.00%+0.36%+2.89%+7.41%NVCNNeovasc0.00%0.00%0.00%0.00%0.00%NVNOenVVeno Medical0.00%-0.20%+8.01%-0.60%+30.63%STIMNeuronetics0.00%+3.98%-31.32%-15.81%-3.69%Everybody laughed when he recommended Netflix (Ad)"This Could be Worth Even More than A.I." Whitney Tilson's nailed many of the most famous stocks of the last 25 years – including Netflix, Amazon, and Apple. Now he's pounding the table on a new technology rolling out across America, which early estimates say could create more wealth than A.I., the personal computer, and the smartphone combined. Click here to see how it could become the No. 1 investment of the next decade.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLUABlueRiver AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ANVCNNeovascN/AN/AN/AN/AN/AN/AN/AN/ANVNOenVVeno Medical0.019 of 5 stars0.01.00.00.00.01.70.6STIMNeuronetics2.4295 of 5 stars3.53.00.00.02.51.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLUABlueRiver AcquisitionN/AN/AN/AN/ANVCNNeovascN/AN/AN/AN/ANVNOenVVeno MedicalN/AN/AN/AN/ASTIMNeuronetics3.00Buy$8.00216.21% UpsideCurrent Analyst RatingsLatest NVCN, STIM, BLUA, and NVNO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2024STIMNeuroneticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform3/26/2024STIMNeuroneticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform3/6/2024STIMNeuroneticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$7.00 ➝ $8.00(Data available from 5/20/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLUABlueRiver AcquisitionN/AN/AN/AN/A($0.72) per shareN/ANVCNNeovasc$3.81M21.60N/AN/A$5.77 per share5.20NVNOenVVeno MedicalN/AN/AN/AN/A$3.47 per shareN/ASTIMNeuronetics$71.35M1.06N/AN/A$1.18 per share2.14Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLUABlueRiver Acquisition-$5.28MN/A0.00∞N/AN/AN/A-34.53%N/ANVCNNeovasc-$41.20M-$15.08N/A∞N/A-1,082.92%-127.25%-80.31%N/ANVNOenVVeno Medical-$23.52M-$1.66N/AN/AN/AN/A-62.17%-57.58%7/29/2024 (Estimated)STIMNeuronetics-$30.19M-$0.96N/AN/AN/A-37.61%-75.84%-26.67%8/13/2024 (Estimated)Latest NVCN, STIM, BLUA, and NVNO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2024Q1 2024NVNOenVVeno MedicalN/A-$0.31-$0.31-$0.31N/AN/A3/5/202412/31/2023STIMNeuronetics-$0.26-$0.19+$0.07-$0.19$19.73 million$20.31 million 2/29/2024Q4 2023NVNOenVVeno MedicalN/A-$0.32-$0.32-$0.32N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLUABlueRiver AcquisitionN/AN/AN/AN/AN/ANVCNNeovascN/AN/AN/AN/AN/ANVNOenVVeno MedicalN/AN/AN/AN/AN/ASTIMNeuroneticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLUABlueRiver AcquisitionN/A0.010.01NVCNNeovasc0.802.962.85NVNOenVVeno MedicalN/A29.0829.08STIMNeuronetics2.155.655.18OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLUABlueRiver Acquisition22.34%NVCNNeovasc1.64%NVNOenVVeno Medical34.71%STIMNeuronetics53.59%Insider OwnershipCompanyInsider OwnershipBLUABlueRiver Acquisition78.98%NVCNNeovascN/ANVNOenVVeno Medical17.00%STIMNeuronetics9.80%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBLUABlueRiver Acquisition38.73 million1.84 millionNot OptionableNVCNNeovasc492.74 millionN/ANot OptionableNVNOenVVeno Medical1913.33 million11.06 millionOptionableSTIMNeuronetics20330.00 million27.06 millionOptionableNVCN, STIM, BLUA, and NVNO HeadlinesRecent News About These CompaniesMay 16, 2024 | americanbankingnews.comWilliam Blair Upgrades Neuronetics (NASDAQ:STIM) to OutperformMay 15, 2024 | msn.comWilliam Blair Upgrades Neuronetics (STIM)May 15, 2024 | cweb.comNeuronetics Earns an Upgrade at William BlairMay 15, 2024 | globenewswire.comHumana Is First Commercial Payer to Address TMS Therapy Coverage for AdolescentsMay 14, 2024 | marketbeat.comNeuronetics (NASDAQ:STIM) Upgraded to "Outperform" at William BlairMay 11, 2024 | americanbankingnews.comQ2 2024 Earnings Estimate for Neuronetics, Inc. (NASDAQ:STIM) Issued By William BlairMay 10, 2024 | msn.comNeuronetics Boasts 12% Revenue Increase, Expands Depression Treatment SectorMay 10, 2024 | marketbeat.comQ2 2024 EPS Estimates for Neuronetics, Inc. Cut by William Blair (NASDAQ:STIM)May 9, 2024 | finance.yahoo.comNeuronetics, Inc. (NASDAQ:STIM) First-Quarter Results: Here's What Analysts Are Forecasting For This YearMay 9, 2024 | seekingalpha.comNeuronetics: Reality Set InMay 8, 2024 | markets.businessinsider.comStrong Buy Rating for Neuronetics Backed by Solid Financials and Growth ProspectsMay 8, 2024 | finance.yahoo.comNeuronetics, Inc. (NASDAQ:STIM) Q1 2024 Earnings Call TranscriptMay 8, 2024 | markets.businessinsider.comBuy Rating on Neuronetics: Solid Fundamentals and Growth Despite ChallengesMay 8, 2024 | finance.yahoo.comNeuronetics Inc (STIM) (Q1 2024) Earnings Call Transcript Highlights: Strategic Growth Amidst ...May 8, 2024 | wsj.comNeuronetics Inc.May 7, 2024 | msn.comNeuronetics GAAP EPS of -$0.27 beats by $0.04, revenue of $17.42M beats by $0.3MMay 7, 2024 | msn.comSTIM Stock Earnings: Neuronetics Beats EPS, Beats Revenue for Q1 2024May 7, 2024 | finance.yahoo.comNeuronetics Inc (STIM) Reports Q1 2024 Earnings: Revenue Surpasses Estimates, Narrowing LossesMay 7, 2024 | zacks.comNeuronetics (STIM) Reports Q1 Loss, Tops Revenue EstimatesMay 7, 2024 | globenewswire.comNeuronetics Reports Record First Quarter 2024 Financial and Operating ResultsMay 6, 2024 | msn.comNeuronetics Q1 2024 Earnings PreviewNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesLockheed Martin Stock Aims for a Fresh All-Time HighApril 23, 2024 9:59 AMView Lockheed Martin Stock Aims for a Fresh All-Time HighMcDonald’s Trend Following Signal is an Opportunity TodayApril 30, 2024 9:45 AMView McDonald’s Trend Following Signal is an Opportunity TodayIBM Sings the Blues on Mixed Pockets of Strength May 1, 2024 7:00 AMView IBM Sings the Blues on Mixed Pockets of Strength On Shares Move Higher in Race to a New All-Time HighMay 14, 2024 10:05 AMView On Shares Move Higher in Race to a New All-Time HighChegg Chokes on AI Attempt, CEO Talks it Up as He Passes Torch May 8, 2024 7:30 AMView Chegg Chokes on AI Attempt, CEO Talks it Up as He Passes Torch All HeadlinesCompany DescriptionsBlueRiver AcquisitionNYSE:BLUABlueRiver Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to identify business opportunities in the field of technology, media, telecom, and entertainment industries. The company was incorporated in 2020 and is based in San Antonio, Texas.NeovascNASDAQ:NVCNNeovasc, Inc. engages in the development, manufacture and marketing of medical devices. It focuses on Neovast Tiara and Neovasc Reducer products. The company was founded on November 2, 2000 and is headquartered in Richmond, Canada.enVVeno MedicalNASDAQ:NVNOenVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial. NeuroneticsNASDAQ:STIMNeuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.